Oxford Glyco works in the emerging field of proteomics, a comprehensive study of proteins. Successfully integrated proteomics with genomics to create an innovative proprietary drug discovery platform that allows the separation, identification, and characterization of proteins on an industrial scale. In August 2003, Oxford Glyco was acquired by Celltech Group plc is one of Europe's largest biotechnology companies, with an innovative development pipeline, funded by its profitable, cash-generative pharmaceutical business. Celltech also possesses drug discovery capabilities of exceptional strength, including a leading position in antibody engineering.
